---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-079880"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T11:58:01.766956+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics files prospectus supplement for up to $80M ATM stock offering

## Summary
- Filed prospectus supplement to sell up to $80M of common stock via ATM program with Canaccord Genuity.
- ATM program established April 3, 2025; supplement filed August 18, 2025.
- Honigman LLP issued validity opinion on shares; counsel's opinion filed as Exhibit 5.1.
- Shares to be sold through any method deemed an 'at the market' offering under Rule 415(a)(4).

## SEC filing metadata
- accession: 0001104659-25-079880
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925079880/0001104659-25-079880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925079880/tm2523368d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-079880
- JSON: https://secwatch.observer/filing/0001104659-25-079880.json
- Plain text: https://secwatch.observer/filing/0001104659-25-079880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.